| Q41242898 | "Indefinite for Dysplasia" in Barrett's Esophagus: Inflammation and DNA Content Abnormality are Significant Predictors of Early Detection of Neoplasia |
| Q36328330 | 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients |
| Q24626024 | A Large-scale genetic association study of esophageal adenocarcinoma risk |
| Q92410485 | A Model Shows Utility in Predicting Postoperative Recurrence and Distant Metastasis in Curatively Resected Esophageal Squamous Cell Cancer |
| Q38925807 | A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus |
| Q47108241 | A Novel Prognostic Scoring System Using Inflammatory Response Biomarkers for Esophageal Squamous Cell Carcinoma |
| Q37114501 | A clinical risk prediction model for Barrett esophagus. |
| Q43724046 | A cost and benefit study of esophagectomy for patients with esophageal cancer |
| Q34217680 | A cross-sectional analysis of the prevalence of Barrett esophagus in otolaryngology patients with laryngeal symptoms |
| Q36753025 | A newly identified susceptibility locus near FOXP1 modifies the association of gastroesophageal reflux with Barrett's esophagus |
| Q38731147 | A non-endoscopic device to sample the oesophageal microbiota: a case-control study |
| Q40039766 | A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett's associated adenocarcinoma |
| Q37697608 | A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction |
| Q50524924 | A population-based analysis of esophageal and gastric cardia adenocarcinomas in Ontario, Canada: incidence, risk factors, and regional variation. |
| Q36597089 | A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma |
| Q30493653 | A segregation analysis of Barrett's esophagus and associated adenocarcinomas. |
| Q34030606 | Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies |
| Q41784546 | Accomplishments in 2007 in the management of advanced gastroesophageal cancer |
| Q37468829 | Accomplishments in 2008 in the management of advanced gastroesophageal cancer. |
| Q64978553 | Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. |
| Q37770081 | Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies |
| Q46947615 | Adenocarcinoma of the esophagus in the young |
| Q35114043 | Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States |
| Q35890113 | Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease |
| Q27021200 | Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review |
| Q36910400 | Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma |
| Q37691902 | Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). |
| Q37678177 | Age at onset of GERD symptoms predicts risk of Barrett's esophagus |
| Q36144148 | Airborne occupational exposures and risk of oesophageal and cardia adenocarcinoma |
| Q37176043 | Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus |
| Q35673305 | American Gastroenterological Association technical review on the management of Barrett's esophagus |
| Q48257252 | An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer. |
| Q90643278 | An NF90/long noncoding RNA-LET/miR-548k feedback amplification loop controls esophageal squamous cell carcinoma progression |
| Q40468473 | An age-period-cohort analysis of obesity and incident esophageal adenocarcinoma among white males. |
| Q35154047 | Angle-resolved low coherence interferometry for detection of dysplasia in Barrett's esophagus |
| Q27007387 | Angle-resolved low-coherence interferometry: an optical biopsy technique for clinical detection of dysplasia in Barrett's esophagus |
| Q46535114 | Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer? |
| Q82589859 | Argon plasma coagulation versus endoscopic mucosal resection in patients with dysplastic Barrett's esophagus |
| Q36776993 | Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort |
| Q85094702 | Association of Adenocarcinomas of the Distal Esophagus, “Gastroesophageal Junction,” and “Gastric Cardia” With Gastric Pathology |
| Q33709588 | Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome |
| Q35681702 | Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas |
| Q53394190 | Association of HOTAIR expression with PI3K/Akt pathway activation in adenocarcinoma of esophagogastric junction. |
| Q36893433 | Association of insulin and insulin-like growth factors with Barrett's oesophagus. |
| Q64916804 | Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men. |
| Q36932731 | Associations of Serum Adiponectin and Leptin With Barrett's Esophagus. |
| Q37098306 | B7-H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukin-6/signal transducer and activator of transcription 3 pathway activation |
| Q52965377 | BTG3 upregulation induces cell apoptosis and suppresses invasion in esophageal adenocarcinoma. |
| Q37542918 | Barrett esophagus: histology and pathology for the clinician |
| Q37591976 | Barrett esophagus: when to endoscope |
| Q34471340 | Barrett's Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research |
| Q54232649 | Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really? |
| Q36014649 | Barrett's Esophagus: Emerging Knowledge and Management Strategies |
| Q37883067 | Barrett's adenocarcinoma of the esophagus: better outcomes through new methods of diagnosis and treatment |
| Q36162518 | Barrett's esophagus: A review of diagnostic criteria, clinical surveillance practices and new developments |
| Q37812916 | Barrett's esophagus: Clinical issues. |
| Q38536012 | Barrett's esophagus: Incidence, etiology, pathophysiology, prevention and treatment |
| Q37861001 | Barrett's esophagus: a review of the literature |
| Q39097596 | Barrett's esophagus: diagnosis and management |
| Q39992700 | Barrett's esophagus: endoscopic treatments II. |
| Q38363283 | Barrett's esophagus: recent insights into pathogenesis and cellular ontogeny. |
| Q37243629 | Barrett's esophagus: where do we stand? |
| Q54290278 | Barrett's oesophagus |
| Q37443917 | Barrett's oesophagus: an ideal model to study cancer genetics |
| Q91763142 | Barretts's carcinogenesis |
| Q46316834 | Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR). |
| Q36649565 | Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. |
| Q39750274 | Bile acid reflux contributes to development of esophageal adenocarcinoma via activation of phosphatidylinositol-specific phospholipase Cgamma2 and NADPH oxidase NOX5-S. |
| Q34448115 | Biomarkers of Barrett's esophagus |
| Q36504770 | Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium |
| Q34576888 | Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study |
| Q35662212 | Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review |
| Q80588220 | COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease |
| Q64904638 | Can proximal Gastrectomy Be Justified for Advanced Adenocarcinoma of the Esophagogastric Junction? |
| Q55242896 | Cell culture models for studying the development of Barrett's esophagus: a systematic review. |
| Q43112741 | Centralization of esophageal cancer surgery: the right thing to do is seldom easy |
| Q31021539 | Changing incidence of esophageal cancer among white women: analysis of SEER data (1992-2010). |
| Q39090046 | Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. |
| Q38541163 | Chemokines and their receptors in esophageal cancer--the systematic review and future perspectives |
| Q57143240 | Chemoprevention of esophageal adenocarcinoma in a rat model by ursodeoxycholic acid |
| Q37198249 | Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma |
| Q33695312 | Cigarette smoking is a modifiable risk factor for Barrett's oesophagus |
| Q57817283 | Circ-DLG1 promotes the proliferation of esophageal squamous cell carcinoma |
| Q37345876 | Circular RNA has_circ_0067934 is upregulated in esophageal squamous cell carcinoma and promoted proliferation |
| Q37505223 | Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study |
| Q37447965 | Circulating miRNA profile in esophageal adenocarcinoma |
| Q41564057 | Circumferential Locations of Different Shapes of Short-segment Barrett's Esophagus |
| Q45022480 | Clinical impact of lymphadenectomy extent in resectable esophageal cancer |
| Q36278127 | Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer |
| Q24596151 | Clinical practice. Gastroesophageal reflux disease |
| Q50334108 | Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer. |
| Q36575789 | Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study |
| Q86895118 | Columnar metaplasia in a surgical mouse model of gastro-esophageal reflux disease is not derived from bone marrow-derived cell |
| Q92697253 | Combined EsophaCap cytology and MUC2 immunohistochemistry for screening of intestinal metaplasia, dysplasia and carcinoma |
| Q64963280 | Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma. |
| Q34603498 | Comparative acceptability of transnasal esophagoscopy and esophageal capsule esophagoscopy: a randomized, controlled trial in veterans |
| Q41374462 | Comparative diagnostic performance of volumetric laser endomicroscopy and confocal laser endomicroscopy in the detection of dysplasia associated with Barrett's esophagus |
| Q39636368 | Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. |
| Q42053177 | Comparison of Clinicopathological Characteristics in the Patients with Cardiac Cancer with or without Esophagogastric Junctional Invasion: A Single-Center Retrospective Cohort Study |
| Q33717444 | Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells |
| Q30579739 | Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study |
| Q64094433 | Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis |
| Q36153084 | Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarcinoma: Retrospective Cohort Study, a Single Institution, High Volume Experience in China |
| Q61799774 | Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples |
| Q36822873 | Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results. |
| Q97527060 | Cryoballoon ablation for treatment of patients with refractory esophageal neoplasia after first line endoscopic eradication therapy |
| Q33760596 | Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma |
| Q35972032 | Current status and future perspectives on the etiology of esophageal adenocarcinoma |
| Q40932494 | Current status of advanced gastrointestinal endoscopy training fellowships in the United States |
| Q34048027 | Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer |
| Q35151182 | Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies. |
| Q54317604 | DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma. |
| Q34228955 | Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer |
| Q84597899 | Decreasing morbidity and mortality in 100 consecutive minimally invasive esophagectomies |
| Q81753352 | Dendritic cells in Barrett's esophagus and esophageal adenocarcinoma |
| Q35159625 | Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells |
| Q35846865 | Detection of fluorescent organic nanoparticles by confocal laser endomicroscopy in a rat model of Barrett's esophageal adenocarcinoma. |
| Q39344023 | Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium |
| Q37716894 | Development of a program to train physician extenders to perform transnasal esophagoscopy and screen for Barrett's esophagus |
| Q93144923 | Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium |
| Q41622143 | Diabetes mellitus carries a risk of esophageal cancer: A meta-analysis |
| Q37055792 | Diagnosis and management of Barrett's esophagus |
| Q55177484 | Diagnosis and treatment of superficial esophageal cancer. |
| Q26753870 | Diagnostics and Early Diagnosis of Esophageal Cancer |
| Q37327500 | Dietary antioxidants, fruits, and vegetables and the risk of Barrett's esophagus |
| Q36038972 | Dietary fruit, vegetable, fat, and red and processed meat intakes and Barrett's esophagus risk: a systematic review and meta-analysis |
| Q36629369 | Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study |
| Q36877248 | Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus |
| Q37361998 | Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database |
| Q34571053 | Discovery and validation of Barrett's esophagus microRNA transcriptome by next generation sequencing |
| Q64262942 | Do doctors who order more routine medical tests diagnose more cancers? A population-based study from Ontario Canada |
| Q91962775 | Do pathologists agree with each other on the histological assessment of pT1b oesophageal adenocarcinoma? |
| Q38056614 | Do proton pump inhibitors protect against cancer progression in GERD? |
| Q44512499 | Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?-a SEER Database Analysis. |
| Q37123537 | Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? |
| Q36117607 | Ductal metaplasia in oesophageal submucosal glands is associated with inflammation and oesophageal adenocarcinoma |
| Q80173104 | Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats |
| Q34476331 | Durability and predictors of successful radiofrequency ablation for Barrett's esophagus |
| Q58484694 | Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection |
| Q26825349 | Early events during neoplastic progression in Barrett's esophagus |
| Q50188597 | Effect of cholecystectomy on gastric and esophageal bile reflux in patients with upper gastrointestinal symptoms |
| Q45050582 | Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States |
| Q44979609 | Effect of proton pump inhibitor therapy on inflammatory changes in the gastric cardia (carditis). |
| Q36719793 | Effectiveness of focal vs. balloon radiofrequency ablation devices in the treatment of Barrett's esophagus |
| Q37159084 | Effects of preceding endoscopic mucosal resection on the efficacy and safety of radiofrequency ablation for treatment of Barrett's esophagus: results from the United States Radiofrequency Ablation Registry |
| Q35093648 | Effects of refluxate pH values on duodenogastroesophageal reflux-induced esophageal adenocarcinoma |
| Q42705165 | Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort study |
| Q64112796 | Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma |
| Q37787343 | Endoscopic Ultrasound Does Not Accurately Stage Early Adenocarcinoma or High-Grade Dysplasia of the Esophagus |
| Q37274429 | Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus |
| Q26765243 | Endoscopic imaging of Barrett's esophagus |
| Q34325283 | Endoscopic management of Barrett's esophagus: advances in endoscopic techniques |
| Q35022528 | Endoscopic mucosal resection results in change of histologic diagnosis in Barrett's esophagus patients with visible and flat neoplasia: a multicenter cohort study. |
| Q38567106 | Endoscopic resection techniques and ablative therapies for Barrett's neoplasia |
| Q24620067 | Epidemiologic differences in esophageal cancer between Asian and Western populations |
| Q43124349 | Epidemiology and biology of esophageal cancer. |
| Q35147677 | Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study |
| Q37777073 | Epidemiology of Adenocarcinoma of the Esophagus, Gastric Cardia, and Upper Gastric Third |
| Q60956958 | Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea |
| Q41906748 | Epithelial mesenchymal transition and cancer stem cells in esophageal adenocarcinoma originating from Barrett's esophagus |
| Q35984037 | Equilibria of humans and our indigenous microbiota affecting asthma |
| Q34344181 | Esophageal Adenocarcinoma and Its Rare Association with Barrett's Esophagus in Henan, China |
| Q80825019 | Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan |
| Q37169303 | Esophageal adenocarcinoma arising in Barrett esophagus |
| Q33932460 | Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy |
| Q36322299 | Esophageal cancer in Canada: trends according to morphology and anatomical location |
| Q36439476 | Esophageal cancer incidence and mortality in China, 2010. |
| Q38848309 | Esophageal surgery in Italy. Criteria to identify the hospital units and the tertiary referral centers entitled to perform it. |
| Q44070284 | Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome. |
| Q55434774 | Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study. |
| Q36419173 | Ethnicity in relation to incidence of oesophageal and gastric cancer in England |
| Q37598619 | Evaluation and treatment of superficial esophageal cancer |
| Q33872723 | Evaluation of Barrett esophagus by multiphoton microscopy |
| Q42407540 | Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction |
| Q33866912 | Evaluation of quantitative image analysis criteria for the high-resolution microendoscopic detection of neoplasia in Barrett's esophagus |
| Q30249468 | Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. |
| Q37522656 | Evolving management of metaplasia and dysplasia in Barrett's epithelium |
| Q33605428 | Exercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus |
| Q36918993 | Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity |
| Q33723590 | Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. |
| Q36783235 | Exposure to gastric juice may not cause adenocarcinogenesis of the esophagus |
| Q33613989 | Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma |
| Q86030207 | Expression of SOX9 and CDX2 in nongoblet columnar-lined esophagus predicts the detection of Barrett's esophagus during follow-up |
| Q37105819 | Failure patterns in patients with esophageal cancer treated with definitive chemoradiation |
| Q83774672 | Familial Barrett's esophagus: clues to genetic risks for esophageal adenocarcinoma |
| Q37558800 | Family history of cancer and gastroesophageal disorders and risk of esophageal and gastric adenocarcinomas: a case-control study |
| Q35608138 | Fascin and CK4 as biomarkers for esophageal squamous cell carcinoma. |
| Q34132822 | Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video) |
| Q39117047 | Fluorescence Imaging for Cancer Screening and Surveillance |
| Q37540092 | Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia |
| Q54498016 | Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. |
| Q39160690 | From Heartburn to Barrett's Esophagus, and Beyond |
| Q34764159 | GERD symptoms in the general population: prevalence and severity versus care-seeking patients |
| Q37063944 | Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma |
| Q37702201 | Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. |
| Q42534789 | Gastroesophageal reflux disease: From heartburn to cancer |
| Q37705870 | Genetic polymorphisms in TERT are associated with increased risk of esophageal cancer |
| Q33903445 | Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group |
| Q36584224 | Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group |
| Q33503736 | Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors |
| Q51121654 | Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis. |
| Q45907163 | Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study. |
| Q51101393 | Globular adiponectin inhibits leptin-stimulated esophageal adenocarcinoma cell proliferation via adiponectin receptor 2-mediated suppression of UHRF1. |
| Q33557802 | H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma |
| Q35111575 | HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. |
| Q55302141 | Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma. |
| Q36782105 | Helicobacter pylori activates the TLR2/NLRP3/caspase-1/IL-18 axis to induce regulatory T-cells, establish persistent infection and promote tolerance to allergens |
| Q34380714 | Helicobacter pylori and Esophageal Disease: Wake-up Call? |
| Q50931631 | Helicobacter pylori and Extragastric Diseases. |
| Q26992042 | Helicobacter pylori: friend or foe? |
| Q37163173 | Hemochromatosis gene status as a risk factor for Barrett's esophagus |
| Q33794854 | High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death |
| Q37726762 | High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma |
| Q81795321 | Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease |
| Q39163004 | Hnf4α is a key gene that can generate columnar metaplasia in oesophageal epithelium. |
| Q35023980 | Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women |
| Q34434005 | IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas |
| Q92128790 | IL-1RA suppresses esophageal cancer cell growth by blocking IL-1α |
| Q41954921 | Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma. |
| Q47561735 | Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus |
| Q87857057 | Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence |
| Q41904650 | Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction |
| Q58752113 | Impact of the development of an endoscopic eradication program for Barrett's esophagus with high grade dysplasia or early adenocarcinoma on the frequency of surgery |
| Q37838811 | Importance of a multidisciplinary approach for the treatment of Barrett's esophagus |
| Q37461032 | In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks |
| Q49418125 | In vitro study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction |
| Q30556995 | In vivo molecular imaging of Barrett's esophagus with confocal laser endomicroscopy |
| Q41848298 | In vivo white light and contrast-enhanced vital-dye fluorescence imaging of Barrett's-related neoplasia in a single-endoscopic insertion |
| Q40242331 | Incidence and survival differences in esophageal cancer among ethnic groups in the United States |
| Q31044821 | Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study |
| Q26853668 | Incidence and treatment of brain metastasis in patients with esophageal carcinoma |
| Q36672337 | Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus |
| Q35012664 | Incidence of brain metastasis in patients with esophageal carcinoma. |
| Q42448630 | Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia. |
| Q36635061 | Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1 |
| Q39739602 | Increasing incidence of Barrett's oesophagus: a population-based study |
| Q57813400 | Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium |
| Q34235853 | Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome |
| Q33840598 | Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. |
| Q45844685 | Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus |
| Q36719828 | Influence of reflux and central obesity on intercellular space diameter of esophageal squamous epithelium |
| Q36097512 | Influence of sex on the survival of patients with esophageal cancer. |
| Q44893920 | Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation |
| Q84590351 | Influence of young age on outcome after esophagectomy for cancer |
| Q39561604 | Insulin/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis |
| Q36469187 | Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma |
| Q34143984 | Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer |
| Q37257157 | Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation |
| Q82930412 | Introduction: esophagus, dysplasia, and early esophageal adenocarcinoma: managing the transition |
| Q37655360 | Is there a role for anything other than a Nissen's operation? |
| Q30411418 | Laryngopharyngeal reflux: diagnosis, treatment, and latest research |
| Q55364039 | Length of Barrett's segment predicts failure of eradication in radiofrequency ablation for Barrett's esophagus: a retrospective cohort study. |
| Q34677521 | LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus? |
| Q37101225 | Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas |
| Q37235519 | Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma |
| Q36722246 | Long non-coding RNA-Low Expression in Tumor inhibits the invasion and metastasis of esophageal squamous cell carcinoma by regulating p53 expression |
| Q58732829 | Long non-coding RNAs in esophageal cancer: molecular mechanisms, functions, and potential applications |
| Q38910164 | Long noncoding RNA CCAT2 correlates with smoking in esophageal squamous cell carcinoma |
| Q37786234 | Long-term Follow-up After Anti-reflux Surgery in Patients with Barrett’s Esophagus |
| Q41585368 | Long-term results of the mucosal ablation of Barrett's esophagus: efficacy and recurrence |
| Q35570961 | Long-term safety concerns of antiresorptive therapy |
| Q36334816 | Long-term survival from adenocarcinoma of the esophagus after transthoracic and transhiatal esophagectomy |
| Q83245149 | Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection |
| Q34258256 | MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status |
| Q28749063 | Malignant Transformation of Non-Neoplastic Barrett's Epithelial Cells through Well-Defined Genetic Manipulations |
| Q38071221 | Management of Barrett's esophageal carcinoma |
| Q38042937 | Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development |
| Q55001719 | Management of gastroesophageal reflux disease in adults: a pharmacist’s perspective. |
| Q54940434 | Matrix metalloproteinase (MMP)-7 in Barrett's esophagus and esophageal adenocarcinoma: expression, metabolism, and functional significance. |
| Q33905941 | Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus |
| Q34047762 | Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus |
| Q36490960 | MicroRNA expression profiles of esophageal cancer |
| Q36717252 | MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma |
| Q36101722 | MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma |
| Q37777088 | Molecular Response Prediction in Multimodality Treatment for Adenocarcinoma of the Esophagus and Esophagogastric Junction |
| Q37876081 | Molecular imaging for guiding oncologic prognosis and therapy in esophageal adenocarcinoma |
| Q34508850 | Molecular markers and imaging tools to identify malignant potential in Barrett's esophagus |
| Q26471049 | Molecular-targeted first-line therapy for advanced gastric cancer |
| Q33750142 | Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade |
| Q38260734 | Multicentric Adenocarcinomas in a Long-Segment of Barrett's Esophagus. |
| Q89272213 | Multimodal treatment in locally advanced gastric cancer |
| Q38256334 | Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects |
| Q39014956 | Multiple Meningocerebral Metastasis and Extensive Skull Metastasis from Squamous Cell Carcinoma of Esophagus: A Case Report and Review of Literature |
| Q35167329 | Murine and human tissue-engineered esophagus form from sufficient stem/progenitor cells and do not require microdesigned biomaterials |
| Q64230847 | Mutational load may predict risk of progression in patients with Barrett's oesophagus and indefinite for dysplasia: a pilot study |
| Q36776711 | NADPH oxidase NOX5-S and nuclear factor κB1 mediate acid-induced microsomal prostaglandin E synthase-1 expression in Barrett's esophageal adenocarcinoma cells |
| Q41037588 | Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes |
| Q34063710 | Neoadjuvant treatment of esophageal cancer |
| Q36392390 | Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? |
| Q37685846 | No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus |
| Q36571216 | Noncoding RNAs and Cancer. |
| Q90642720 | OSeac: An Online Survival Analysis Tool for Esophageal Adenocarcinoma |
| Q37576268 | Obesity and GERD. |
| Q36172769 | Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link? |
| Q55113271 | Obesity as a surgical risk factor. |
| Q37296589 | Oesophageal biopsies are insufficient to predict final histology after endoscopic resection in early Barrett's neoplasia |
| Q33268091 | Oesophageal cancer mortality in Spain: a spatial analysis |
| Q34325751 | Oesophageal carcinoma |
| Q34259612 | Optical Imaging with a Cathepsin B Activated Probe for the Enhanced Detection of Esophageal Adenocarcinoma by Dual Channel Fluorescent Upper GI Endoscopy |
| Q37967701 | Optimal management of Barrett's esophagus: pharmacologic, endoscopic, and surgical interventions |
| Q33599536 | Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up |
| Q84070200 | Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus |
| Q55077833 | Outcomes of the Surgical Treatment for Adenocarcinoma of the Cardia - Single Institution Experience. |
| Q47237442 | Overdiagnosis across medical disciplines: a scoping review |
| Q38558734 | Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. |
| Q39793635 | Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells |
| Q34063695 | Pathophysiology and treatment of Barrett's esophagus |
| Q33807272 | Patient experiences with surveillance endoscopy: a qualitative study |
| Q41994336 | Patient with advanced gastric cancer responds twice to the same systemic therapy. |
| Q37121698 | Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113 |
| Q35040026 | Photodynamic therapy vs radiofrequency ablation for Barrett's dysplasia: efficacy, safety and cost-comparison |
| Q46217013 | Polymorphism Arg290Arg in esophageal-cancer-related gene 1 (ECRG1) is a prognostic factor for survival in esophageal cancer |
| Q41705186 | Porcine Esophageal Submucosal Gland Culture Model Shows Capacity for Proliferation and Differentiation |
| Q36936947 | Positron emission tomography for initial staging of esophageal cancer among medicare beneficiaries |
| Q51559882 | Prague C&M and Japanese criteria: shades of Barrett's esophagus endoscopic diagnosis. |
| Q31050730 | Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm |
| Q35583933 | Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers |
| Q37519245 | Prediction of Barrett's esophagus among men. |
| Q39218520 | Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry |
| Q36127891 | Predictors of progression in Barrett's esophagus: current knowledge and future directions |
| Q34490562 | Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus |
| Q49382552 | Preoperative Prognostic Nutritional Index Predicts Long-Term Surgical Outcomes in Patients with Esophageal Squamous Cell Carcinoma |
| Q34309843 | Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus |
| Q38919854 | Preventing anastomotic complications: early results of laparoscopic gastric devascularization two weeks prior to minimally invasive esophagectomy |
| Q41865361 | Probe-Based Confocal Laser Endomicroscopy to Guide Real-Time Endoscopic Therapy in Barrett's Esophagus with Dysplasia |
| Q33702570 | Probing the link between oestrogen receptors and oesophageal cancer. |
| Q49335043 | Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy. |
| Q58695588 | Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis |
| Q35609733 | Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma |
| Q35043996 | Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma |
| Q37984273 | Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis |
| Q35129698 | Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy |
| Q28390556 | Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium |
| Q38214785 | Progression of Barrett oesophagus: role of endoscopic and histological predictors |
| Q37195204 | Prospective evaluation of the clinical utility of endoscopic submucosal dissection (ESD) in patients with Barrett's esophagus: a Western center experience |
| Q47245519 | Protein-Protein Interaction Network Analysis for a Biomarker Panel Related to Human Esophageal Adenocarcinoma |
| Q36245569 | Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis |
| Q38332589 | Proton Pump Inhibitors: The Culprit for Barrett's Esophagus? |
| Q36715059 | Psychosocial factors and their association with reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma |
| Q38599611 | Quantitation of spatial and temporal variability of biomarkers for Barrett's Esophagus |
| Q33771039 | Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins. |
| Q36405467 | Quantitative analysis of high-resolution microendoscopic images for diagnosis of neoplasia in patients with Barrett's esophagus |
| Q37163647 | Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. |
| Q38793640 | Radiofrequency ablation coupled with Roux-en-Y gastric bypass: a treatment option for morbidly obese patients with Barrett's esophagus |
| Q38221968 | Radiofrequency ablation for Barrett's-associated intramucosal carcinoma: a multi-center follow-up study |
| Q43788473 | Radiofrequency ablation for dysplasia in Barrett's esophagus restores β-catenin activation within esophageal progenitor cells. |
| Q37018314 | Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort |
| Q33956299 | Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial |
| Q50057605 | Recent Advances in Screening for Barrett's Esophagus. |
| Q42181610 | Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials |
| Q90402248 | Recent progress regarding kaempferol for the treatment of various diseases |
| Q38962645 | Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control |
| Q36966394 | Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium |
| Q33746567 | Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis |
| Q34898182 | Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition |
| Q27027551 | Regenerative Medicine Strategies for Esophageal Repair |
| Q38339102 | Regenerative medicine for oesophageal reconstruction after cancer treatment |
| Q33634990 | Regulation of Desmocollin3 Expression by Promoter Hypermethylation is Associated with Advanced Esophageal Adenocarcinomas |
| Q37271695 | Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study |
| Q34509469 | Risk of esophagus cancer in diabetes mellitus: a population-based case-control study in Taiwan |
| Q37538933 | Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance |
| Q90320562 | Role of Proton Pump Inhibitors in Laryngopharyngeal Reflux: Clinical Evaluation in a North Indian Population |
| Q39772570 | Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma |
| Q27009263 | Role of interleukin-6 in Barrett's esophagus pathogenesis |
| Q90644179 | Screening and Prevention of Barrett's Esophagus |
| Q50895346 | Screening and surveillance for Barrett's esophagus-an unresolved dilemma. |
| Q28080445 | Screening for Barrett's Esophagus |
| Q64079648 | Screening for Barrett's Esophagus: Balancing Clinical Value and Cost-effectiveness |
| Q34624586 | Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions |
| Q35291906 | Screening for Barrett's esophagus: results from a population-based survey |
| Q93036280 | Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett's esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: two systematic reviews and one overview of reviews t |
| Q35073431 | Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction |
| Q35863931 | Sex and race and/or ethnicity differences in patients undergoing radiofrequency ablation for Barrett's esophagus: results from the U.S. RFA Registry |
| Q37678910 | Short-Segment Barrett's Esophagus and Adenocarcinoma |
| Q35265620 | Signaling in H2O2-induced increase in cell proliferation in Barrett's esophageal adenocarcinoma cells |
| Q27026253 | Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction |
| Q60044490 | Signatures within the esophageal microbiome are associated with host genetics, age, and disease |
| Q41808019 | Significance of Persistent Nondysplasia Over Multiple Endoscopic Surveillance in Risk Stratification of Patients With Barrett's Esophagus (Gastroenterology 2013;145:548-553, e1) |
| Q35856606 | Significance of paneth cell metaplasia in Barrett esophagus: a morphologic and clinicopathologic study |
| Q36151891 | Simplified classification of capillary pattern in Barrett esophagus using magnifying endoscopy with narrow band imaging: implications for malignant potential and interobserver agreement |
| Q50630067 | Single center experience of endoscopic submucosal dissection (ESD) in early Barrett's adenocarcinoma. |
| Q33902184 | Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression |
| Q35218771 | Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival |
| Q47159246 | Stem cell factor in the serum of patients with esophageal cancer in relation to its histological types |
| Q34025914 | Study of FoxA pioneer factor at silent genes reveals Rfx-repressed enhancer at Cdx2 and a potential indicator of esophageal adenocarcinoma development |
| Q47100285 | Study on the role of transient receptor potential C6 channels in esophageal squamous cell carcinoma radiosensitivity |
| Q26861000 | Surgical indications and optimization of patients for resectable esophageal malignancies |
| Q92189129 | Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma |
| Q39219348 | Synthesis and characterization of anti-EGFR fluorescent nanoparticles for optical molecular imaging |
| Q30559268 | Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results |
| Q37524048 | Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus |
| Q49846671 | The Effect of Endoscopic Surveillance in Patients with Barrett's Esophagus: A Systematic Review and Meta-analysis |
| Q55490107 | The Microenvironment in Barrett's Esophagus Tissue Is Characterized by High FOXP3 and RALDH2 Levels. |
| Q34009616 | The Na+/H+ exchanger controls deoxycholic acid-induced apoptosis by a H+-activated, Na+-dependent ionic shift in esophageal cells |
| Q36693716 | The Serum Concentrations of Chemokine CXCL12 and Its Specific Receptor CXCR4 in Patients with Esophageal Cancer |
| Q33685262 | The association between obesity and GERD: a review of the epidemiological evidence |
| Q36162512 | The association between obesity factor and esophageal caner |
| Q43593864 | The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma |
| Q34235047 | The immune cell composition in Barrett's metaplastic tissue resembles that in normal duodenal tissue |
| Q34625008 | The impact of proton pump inhibitors on the human gastrointestinal microbiome |
| Q46151361 | The impact of reflux composition on mucosal injury and esophageal function |
| Q51736501 | The metaplastic mosaic of Barrett's oesophagus. |
| Q26748604 | The new kid on the block for advanced imaging in Barrett's esophagus: a review of volumetric laser endomicroscopy |
| Q35619274 | The prevalence of Barrett's-esophagus-associated dysplasia in Puerto Rico |
| Q38687715 | The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis |
| Q34374254 | The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection |
| Q53215589 | The role of integrated F-18-FDG-PET scanning in the detection of M1 disease in oesophageal adenocarcinoma and impact on clinical management. |
| Q42358610 | The role of radiation therapy for resectable adenocarcinoma of the gastroesophageal junction |
| Q40319118 | TissueCypher(™): A systems biology approach to anatomic pathology |
| Q36533579 | Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study |
| Q35929463 | Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy |
| Q39797954 | Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement |
| Q35688584 | Treatment of resectable gastric cancer |
| Q34231941 | Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre |
| Q43167565 | Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction |
| Q41788522 | Tumor Biology: Is It Time to Redefine Unresectability? An Extraordinary Case of Gastroesophageal Junctional Adenocarcinoma |
| Q34699973 | Undervalued criteria in the evaluation of multimodal trials for upper GI cancers |
| Q35256138 | Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases |
| Q37068819 | Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappaB pathway |
| Q47615939 | Up-regulated miR-548k promotes esophageal squamous cell carcinoma progression via targeting long noncoding RNA-LET. |
| Q37109094 | Upregulation of MAGEA4 correlates with poor prognosis in patients with early stage of esophageal squamous cell carcinoma |
| Q38943160 | Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma |
| Q89972992 | Validation and Comparison of Tools for Selecting Individuals to Screen for Barrett's Esophagus and Early Neoplasia |
| Q46856335 | Validation of a rodent model of Barrett's esophagus using quantitative gene expression profiling |
| Q80178127 | Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma |
| Q37155234 | Vegetable and fruit intakes and risk of Barrett's esophagus in men and women |
| Q93049011 | Volumetric laser endomicroscopy and optical coherence tomography in Barrett's esophagus: a systematic review and meta-analysis |
| Q47429245 | What are the consequences of the disappearing human microbiota? |
| Q38559655 | Whole slide image cytometry: a novel method to detect abnormal DNA content in Barrett's esophagus. |
| Q95726214 | Wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS) markedly improves detection of esophageal dysplasia and Barrett's esophagus: analysis from a prospective multicenter community-based study |
| Q36031345 | XAF1 is frequently methylated in human esophageal cancer |
| Q45967163 | XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms in esophageal cancer risk: a meta-analysis. |
| Q82734882 | [Increasing incidence of esophageal adenocarcinoma: a new challenge] |
| Q33388259 | p16 mutation spectrum in the premalignant condition Barrett's esophagus |
| Q34848523 | p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis |